Exact Mass: 455.16739060000003
Exact Mass Matches: 455.16739060000003
Found 100 metabolites which its exact mass value is equals to given mass value 455.16739060000003
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
N-(6-Amino-2-methyl-pyridin-3-ylmethyl)-2-(6-methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-acetamide
C22H25N5O4S (455.16271700000004)
Ala Asn His Asp
Ala Asp His Asn
Ala Asp Asn His
Ala His Asp Asn
Ala His Asn Asp
Ala Asn Asp His
Asp Ala His Asn
Asp Ala Asn His
Asp Gly His Gln
Asp Gly Gln His
Asp His Ala Asn
Asp His Gly Gln
Asp His Asn Ala
Asp His Gln Gly
Asp Asn Ala His
Asp Asn His Ala
Asp Gln Gly His
Asp Gln His Gly
Glu Gly His Asn
Glu Gly Asn His
Glu His Gly Asn
Glu His Asn Gly
Glu Asn Gly His
Glu Asn His Gly
Gly Asp His Gln
Gly Asp Gln His
Gly Glu His Asn
Gly Glu Asn His
Gly His Asp Gln
Gly His Glu Asn
Gly His Asn Glu
Gly His Gln Asp
Gly Asn Glu His
Gly Asn His Glu
Gly Gln Asp His
Gly Gln His Asp
His Ala Asp Asn
His Ala Asn Asp
His Asp Ala Asn
His Asp Gly Gln
His Asp Asn Ala
His Asp Gln Gly
His Glu Gly Asn
His Glu Asn Gly
His Gly Asp Gln
His Gly Glu Asn
His Gly Asn Glu
His Gly Gln Asp
His Asn Ala Asp
His Asn Asp Ala
His Asn Glu Gly
His Asn Gly Glu
His Gln Asp Gly
His Gln Gly Asp
Asn Ala Asp His
Asn Ala His Asp
Asn Asp Ala His
Asn Asp His Ala
Asn Glu Gly His
Asn Glu His Gly
Asn Gly Glu His
Asn Gly His Glu
Asn His Ala Asp
Asn His Asp Ala
Asn His Glu Gly
Asn His Gly Glu
Gln Asp Gly His
Gln Asp His Gly
Gln Gly Asp His
Gln Gly His Asp
Gln His Asp Gly
Gln His Gly Asp
16-carboxy-Delta(13)-17,18,19,20-tetranor-N-acetyl-leukotriene E4
C21H29NO8S (455.16137940000004)
Lisdexamfetamine dimesylate
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018765 - Dopamine Uptake Inhibitors D002491 - Central Nervous System Agents > D000697 - Central Nervous System Stimulants C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant C78272 - Agent Affecting Nervous System > C29728 - Anorexiant D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents D049990 - Membrane Transport Modulators
1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]-1-propanone
C29H26ClNO2 (455.16519660000006)
13H-spiro[benzo[c]indeno[2,1-a]carbazole-14,9-fluorene]
Moxifloxacin hydrochloride monohydrate
C21H27ClFN3O5 (455.16231740000006)
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones D004791 - Enzyme Inhibitors
3-(2-Chlorophenyl)-1-(2-{[(1S)-2-hydroxy-1,2-dimethylpropyl]amino}pyrimidin-4-YL)-1-(4-methoxyphenyl)urea
C23H26ClN5O3 (455.17240760000004)
4-(2-amino-3-cyano-5-oxo-5,6,7,8-tetrahydro-4H-chromen-4-yl)-2,6-dimethoxyphenyl morpholine-4-carboxylate
AD57
C22H20F3N7O (455.16813460000003)
AD57 is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src, with greatly reduces mTOR activity[1].
GNE-9815
GNE-9815 (compound 7) is a highly selective, pan-RAF inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for CRAF and BRAF, respectively. GNE-9815 combines with MEK inhibitor Cobimetinib (HY-13064) shows synergistic modulation of MAPK pathway. GNE-9815 can be used in studies of KRAS mutant cancers[1].
(1s,6r,10r,12r,19s,20r,21s)-21-(dimethylamino)-16,20-dihydroxy-12,19-dimethyl-7,11,23-trioxahexacyclo[17.3.1.0²,¹⁸.0³,¹⁵.0⁵,¹³.0⁶,¹⁰]tricosa-2,5(13),15,17-tetraene-4,8,14-trione
[(2r,3r,4r,5s,6r)-2-{[(2s,3r,4r,5r,6s)-4,5-dihydroxy-2-{[(2s)-1-hydroxy-3-oxopropan-2-yl]oxy}-6-methyloxan-3-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]amino acetate
C17H29NO13 (455.16388240000003)
[2-({4,5-dihydroxy-2-[(1-hydroxy-3-oxopropan-2-yl)oxy]-6-methyloxan-3-yl}oxy)-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]amino acetate
C17H29NO13 (455.16388240000003)
(2e,4e)-n-[(3s)-7,9-dichloro-2-hydroxy-8-oxo-1-oxaspiro[4.5]deca-6,9-dien-3-yl]-4,6-dimethyldodeca-2,4-dienimidic acid
3-[({10-amino-10-benzyl-7,9,10a-trihydroxy-3-oxo-1h,2h,5h-pyrrolo[1,2-b]isoquinolin-5-yl}(hydroxy)methylidene)amino]propanoic acid
(1's,14'r)-1'-{[(4s)-3-hydroxy-6-oxo-1h,4h-pyrazino[2,1-b]quinazolin-4-yl]methyl}-13'-oxa-8',11'-diazaspiro[cyclopropane-1,10'-tetracyclo[6.5.1.0²,⁷.0¹¹,¹⁴]tetradecane]-2',4',6'-trien-9'-one
C25H21N5O4 (455.15934660000005)
21-(dimethylamino)-16,20-dihydroxy-12,19-dimethyl-7,11,23-trioxahexacyclo[17.3.1.0²,¹⁸.0³,¹⁵.0⁵,¹³.0⁶,¹⁰]tricosa-2,5(13),15,17-tetraene-4,8,14-trione
(2e,4e,6r)-n-[(2s,3s)-7,9-dichloro-2-hydroxy-8-oxo-1-oxaspiro[4.5]deca-6,9-dien-3-yl]-4,6-dimethyldodeca-2,4-dienimidic acid
(2s)-3-acetyl-2-aminopentanedioic acid; bis(oxindole)
(2e,4e)-n-{7,9-dichloro-2-hydroxy-8-oxo-1-oxaspiro[4.5]deca-6,9-dien-3-yl}-4,6-dimethyldodeca-2,4-dienimidic acid
(1r,6r,10r,12r,19r,20s,21r)-21-(dimethylamino)-16,20-dihydroxy-12,19-dimethyl-7,11,23-trioxahexacyclo[17.3.1.0²,¹⁸.0³,¹⁵.0⁵,¹³.0⁶,¹⁰]tricosa-2,5(13),15,17-tetraene-4,8,14-trione
1'-({3-hydroxy-6-oxo-1h,4h-pyrazino[2,1-b]quinazolin-4-yl}methyl)-13'-oxa-8',11'-diazaspiro[cyclopropane-1,10'-tetracyclo[6.5.1.0²,⁷.0¹¹,¹⁴]tetradecane]-2',4',6'-trien-9'-one
C25H21N5O4 (455.15934660000005)